Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Former InterMune CEO Convicted Of Fraud

by Ann M. Thayer
October 12, 2009 | A version of this story appeared in Volume 87, Issue 41

W . Scott Harkonen, CEO of InterMune from February 1998 through June 2003, was convicted in U.S. District Court for the Northern District of California of wire fraud for disseminating false information about the efficacy of the company’s drug Actimmune (interferon γ-1b) as a treatment for idiopathic pulmonary fibrosis. Most of the company’s Actimmune sales were for non-FDA-approved, or off-label, use of the drug to treat the fatal disease. One year’s treatment cost about $50,000. In October 2006, InterMune agreed to pay about $37 million to resolve criminal charges and civil liability related to illegal promotion of the drug. Harkonen faces up to 20 years in prison.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.